Clinical trials: HIV Reservoir
HIV Infection
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
The overall objective is to determine the influence of timing of ART initiation and alcohol consumption on HIV disease course. ART initiation immediately after HIV infection largely results in smaller HIV reservoir and lower…
- Trial name
- MERLIN (NCT02744040)
- Testing
- ART initiation at time of HIV diagnosis, ART at 24 weeks
- Where
- Peru
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV
Research In Viral Eradication of HIV Reservoirs
This study will be a two-arm prospective 1:1 randomised controlled trial comparing: Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus…
- Trial name
- RIVER (NCT02336074)
- Testing
- Combination Antiretroviral Therapy (cART), Raltegravir, Vorinostat
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
AIDS, HIV
Perturbing of HIV Reservoir With Immune Stimulation
The purpose of this study is to determine the impact of Pneumococcus and Influenza vaccines on the HIV transcriptional activity in individuals who are virologically suppressed for at least 48 weeks on similar ART.
- Trial name
- NCT02707692
- Testing
- Fluarix, Pneumovax
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Diego
Acute HIV Infection
Effects of Intensive cART During Acute/Early HIV Infection
This trial will investigate the efficacy and safety of intensified antiretroviral treatment that includes raltegravir and maraviroc during the early stages of HIV infection.
- Trial name
- NCT01154673
- Testing
- raltegravir, maraviroc, emtricitabine 200mg /tenofovir 300mg
- Where
- 2 sites in Canada
- Volunteers
- 32 people
- Sponsor
- University of Toronto
HIV Infection
HIV Reservoir Reduction With Interleukin-2
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV…
- Trial name
- IL2 (NCT03308786)
- Testing
- Recombinant Interleukin-2
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Western Reserve University
Human Immunodeficiency Virus (HIV)
Romidepsin Plus 3BNC117 Phase 2a Study
The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
- Trial name
- ROADMAP (NCT02850016)
- Testing
- 3BNC117, Romidepsin
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 48 people
- Sponsor
- Rockefeller University
HIV-1 Infection
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
The purpose of this study is to determine whether a two-week course of disulfiram will reduce the HIV-1 latent reservoir in patients on highly active antiretroviral therapy (HAART).
- Trial name
- NCT01286259
- Testing
- Disulfiram
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV Infections
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load < 50…
- Trial name
- PLUS (NCT00884793)
- Testing
- raltegravir, Study NNRTI, Study PI
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
HIV-1 Infection
Analytical Treatment Interruption in HIV Positive Patients
HIV-1 infected patients with normal peripheral blood CD4+ T-cell counts and undetectable viral load will be recruited in four Belgian HIV reference centers.
- Trial name
- ISALA (NCT02590354)
- Testing
- ART interruption
- Where
- 4 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infection
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation.
- Trial name
- EraMune02 (NCT00976404)
- Testing
- DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Robert L. Murphy
HIV
Dolutegravir in Reservoirs
The purpose of this study is to find out how well the HIV medication dolutegravir gets into different parts of the body including blood plasma, special blood cells, and rectal tissue.
- Trial name
- NCT02924389
- Testing
- dolutegravir, Triumeq, Truvada
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Hiv
LoViReT (Low Viral Reservoir Treated Patients)
The main purpose of this study is to unravel the mechanisms by which the "Low Viral Reservoir Treated" patients (LoViReT) maintain extremely low HIV-1 DNA levels despite having initiated cART during chronic HIV-1 infection.
- Trial name
- LoViReT (NCT02972931)
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- IrsiCaixa
Human Immunodeficiency Virus I Infection
MMF for HIV Reservoir Reduction
This is an open label, randomized Phase II study to determine whether Mycophenolate mofetil (MMF) given over 22 months meaningfully decreases the size of participants' HIV reservoir.
- Trial name
- NCT03262441
- Testing
- Mycophenolate Mofetil 500Mg Tab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Background: HIV affects millions of people. The disease may "hide" in the brain, even in people with well-controlled HIV without cancer. Then it may "wake up" and continue.
- Trial name
- NCT03239899
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infection
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART.
- Trial name
- NCT02440789
- Testing
- Sirolimus
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
HIV-1-infection
Therapeutic Vaccination in Treated HIV Disease
The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target…
- Trial name
- NCT03606213
- Testing
- PENNVAX-GP, INO-6145, INO-9012
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Steven Deeks